# OnCo record nct06710288 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06710288/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06710288", "NCT06710288" ;
  schema:name "A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In P"@en ;
  schema:description "A phase 2 trial of Gemcitabine, Nogapendekin alfa inbakicept in ovarian cancer, run by ImmunityBio, Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06710288/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06710288> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2024-11-06" ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/platinum-resistant-ovarian-cancer/> ;
  onco:technologies <https://onco.cc/technologies/cytokine-therapy/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/nogapendekin-alfa/> ;
  onco:companies <https://onco.cc/companies/immunitybio/> .